Stephanie E. Mann

Novel Technique for Assessing Amniotic Fluid Volume: Use of a Three-Dimensional Bladder Scanner

OBJECTIVE Abnormalities of amniotic fluid (AF) volume are associated with significant perinatal morbidity and mortality. Although current ultrasound techniques provide a linear amniotic fluid index (AFI) or 2-D area of AF, these indices have limited correlation with actual AF volume. The bladder volume instrument (BVI) 2500 ultrasound (Diagnostic Ultrasound Corp., Redmond, WA) utilizes a rotating 2 MHz transducer, a computer-defined fluid interface, and computer integration of 12 cross-sectional images to calculate 3-D fluid volume. In term pregnancies with normal AF volume, we previously demonstrated a correlation between the AFI and the 3-D volume as determined by BVI. In the present study, we sought to establish normative gestational values for BVI-determined 3-D volume and the relation to simultaneous AFI determinations. METHODS Following written informed consent, 73 gravidas (17-41 weeks) with uncomplicated pregnancies and normal

Fetal absorption of intra-amniotic aldosterone: effects on urine composition.

OBJECTIVES Amniotic fluid (AF) volume and composition are maintained by a balance of fetal fluid production and resorption. Ovine fetal resorption of peptide hormones (e.g., arginine vasopressin) from the amniotic cavity has been demonstrated, with resultant effects on fetal urine production. The present study was undertaken to determine whether intra-amniotically administered steroid hormones could be absorbed from the amniotic cavity into fetal plasma and whether intra-amniotic aldosterone administration would affect fetal renal sodium and potassium excretion. METHODS Seven singleton fetuses (132 +/- 2 days) were prepared with bladder, vascular, and amniotic cavity catheters. After a 5-day recovery period, a bolus of aldosterone was injected into the amniotic cavity. Fetuses were monitored for an additional 24 hours during which time maternal, fetal, and AF samples were collected at timed intervals. RESULTS After intra-amniotic aldosterone injection, AF aldosterone concentrations increased at 30 minutes and remained elevated for 4 hours after the aldosterone bolus. In response to increased AF aldosterone, fetal plasma aldosterone levels significantly increased by 30 minutes, peaked at 1 hour (17 +/- 4 to 758 +/- 160 pg/mL), and remained elevated for a minimum of 4 hours. Fetal urine sodium excretion significantly decreased and potassium excretion increased. Maternal plasma aldosterone levels increased significantly (25 +/- 10 to 401 +/- 56 pg/mL) but to levels below fetal values. Amniotic fluid and fetal and maternal aldosterone concentrations and fetal urine sodium and potassium excretion returned toward basal levels by 24 hours. CONCLUSION The steroid hormone aldosterone can be absorbed from the amniotic cavity into the fetal circulation and can alter fetal urine electrolyte excretion. These results suggest that the amniotic cavity is a potential route of in utero pharmacologic fetal therapy.